CD274 and cancer: Immune checkpoint blockade can be used to treat cancer effectively since glycolysis in cancer cells can be stimulated by interactions between programmed death ligand 1 (PD-L1) on murine CRC cells and PD1 on T cells, increasing effector T-cell access to glucose 27.